PT876498E - Mistura de vectores de vaccinia recombinantes como vacinas polyenv para hiv - Google Patents

Mistura de vectores de vaccinia recombinantes como vacinas polyenv para hiv

Info

Publication number
PT876498E
PT876498E PT97903823T PT97903823T PT876498E PT 876498 E PT876498 E PT 876498E PT 97903823 T PT97903823 T PT 97903823T PT 97903823 T PT97903823 T PT 97903823T PT 876498 E PT876498 E PT 876498E
Authority
PT
Portugal
Prior art keywords
vacciny
hiv
recombinant
vectors
mixing
Prior art date
Application number
PT97903823T
Other languages
English (en)
Portuguese (pt)
Inventor
Hurwitz Julia
Coleclough Christopher
Owens Randall
Slobod Karen
Original Assignee
St Jude Childrens Res Hospital
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by St Jude Childrens Res Hospital filed Critical St Jude Childrens Res Hospital
Publication of PT876498E publication Critical patent/PT876498E/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/21—Retroviridae, e.g. equine infectious anemia virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C07K14/08—RNA viruses
    • C07K14/15—Retroviridae, e.g. bovine leukaemia virus, feline leukaemia virus human T-cell leukaemia-lymphoma virus
    • C07K14/155—Lentiviridae, e.g. human immunodeficiency virus [HIV], visna-maedi virus or equine infectious anaemia virus
    • C07K14/16—HIV-1 ; HIV-2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5256—Virus expressing foreign proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/53—DNA (RNA) vaccination
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/24011—Poxviridae
    • C12N2710/24111—Orthopoxvirus, e.g. vaccinia virus, variola
    • C12N2710/24141—Use of virus, viral particle or viral elements as a vector
    • C12N2710/24143—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/24011—Poxviridae
    • C12N2710/24111—Orthopoxvirus, e.g. vaccinia virus, variola
    • C12N2710/24171—Demonstrated in vivo effect
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/16011—Human Immunodeficiency Virus, HIV
    • C12N2740/16111—Human Immunodeficiency Virus, HIV concerning HIV env
    • C12N2740/16122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/16011—Human Immunodeficiency Virus, HIV
    • C12N2740/16111—Human Immunodeficiency Virus, HIV concerning HIV env
    • C12N2740/16134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/16011—Human Immunodeficiency Virus, HIV
    • C12N2740/16211—Human Immunodeficiency Virus, HIV concerning HIV gagpol
    • C12N2740/16222—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Virology (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Immunology (AREA)
  • Microbiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • General Engineering & Computer Science (AREA)
  • Wood Science & Technology (AREA)
  • Biochemistry (AREA)
  • Zoology (AREA)
  • Communicable Diseases (AREA)
  • Biotechnology (AREA)
  • Biomedical Technology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Hematology (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Oncology (AREA)
  • AIDS & HIV (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
PT97903823T 1996-01-23 1997-01-23 Mistura de vectores de vaccinia recombinantes como vacinas polyenv para hiv PT876498E (pt)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US08/590,288 US5741492A (en) 1996-01-23 1996-01-23 Preparation and use of viral vectors for mixed envelope protein vaccines against human immunodeficiency viruses

Publications (1)

Publication Number Publication Date
PT876498E true PT876498E (pt) 2005-02-28

Family

ID=24361647

Family Applications (1)

Application Number Title Priority Date Filing Date
PT97903823T PT876498E (pt) 1996-01-23 1997-01-23 Mistura de vectores de vaccinia recombinantes como vacinas polyenv para hiv

Country Status (28)

Country Link
US (3) US5741492A (enExample)
EP (2) EP0876498B1 (enExample)
JP (2) JP2000504326A (enExample)
KR (1) KR100571479B1 (enExample)
CN (1) CN1229501C (enExample)
AP (1) AP1200A (enExample)
AT (1) ATE278790T1 (enExample)
AU (1) AU709174B2 (enExample)
BG (1) BG64711B1 (enExample)
BR (1) BR9707611A (enExample)
CA (1) CA2243570C (enExample)
CZ (1) CZ296575B6 (enExample)
DE (1) DE69731075T2 (enExample)
DK (1) DK0876498T3 (enExample)
EA (1) EA002390B1 (enExample)
ES (1) ES2230596T3 (enExample)
GE (1) GEP20032902B (enExample)
HU (2) HU0402182D0 (enExample)
IL (2) IL125497A (enExample)
NO (1) NO322261B1 (enExample)
NZ (1) NZ331024A (enExample)
OA (1) OA10814A (enExample)
PL (1) PL188641B1 (enExample)
PT (1) PT876498E (enExample)
RO (1) RO120268B1 (enExample)
TR (1) TR199801418T2 (enExample)
UA (1) UA73712C2 (enExample)
WO (1) WO1997027311A1 (enExample)

Families Citing this family (59)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7488485B2 (en) * 2003-09-16 2009-02-10 University Of Kansas Medical Center DNA vaccine compositions and methods of use
US20030138454A1 (en) * 1997-06-09 2003-07-24 Oxxon Pharmaccines, Ltd. Vaccination method
GB9711957D0 (en) * 1997-06-09 1997-08-06 Isis Innovation Methods and reagents for vaccination
US6919318B1 (en) * 1998-04-22 2005-07-19 Chiron Corporation Enhancing immune responses to genetic immunization by using a chemokine
WO1999061049A2 (en) * 1998-05-22 1999-12-02 University Of Massachusetts Medical Center Model for infection by a pathogen using administration of nucleic acids
US6562800B1 (en) * 1998-10-30 2003-05-13 University Of Southern California Use of immunopotentiating sequences for inducing immune response
US6759237B1 (en) * 1998-11-05 2004-07-06 The Trustees Of The University Of Pennsylvania Adeno-associated virus serotype 1 nucleic acid sequences, vectors and host cells containing same
EP1135468B1 (en) 1998-11-10 2010-01-06 University Of North Carolina At Chapel Hill Virus vectors and methods of making and administering the same
EP1141314A2 (en) * 1998-12-31 2001-10-10 Chiron Corporation Polynucleotides encoding antigenic hiv type c polypeptides, polypeptides and uses thereof
US7935805B1 (en) * 1998-12-31 2011-05-03 Novartis Vaccines & Diagnostics, Inc Polynucleotides encoding antigenic HIV Type C polypeptides, polypeptides and uses thereof
AU2221600A (en) 1998-12-31 2000-07-31 Chiron Corporation Improved expression of hiv polypeptides and production of virus-like particles
ATE384795T1 (de) * 1998-12-31 2008-02-15 Novartis Vaccines & Diagnostic Modifizierte hiv env polypeptide
CA2361353A1 (en) * 1999-01-28 2000-08-03 Stichting Biomedical Primate Research Centre Product and method for obtaining specific immunisation with one or more antigens
DE19907485B4 (de) * 1999-02-12 2008-01-17 Strathmann Ag & Co. Virus-Vakzine
US6420545B1 (en) * 1999-05-24 2002-07-16 The Trustees Of The University Of Pennsylvania CD4-independent HIV envelope proteins as vaccines and therapeutics
AU3793701A (en) * 1999-11-29 2001-06-04 Orchid Biosciences, Inc. Methods of identifying optimal drug combinations and compositions thereof
US20040105871A1 (en) * 2000-03-02 2004-06-03 Robinson Harriet L. Compositions and methods for generating an immune response
US20020106798A1 (en) 2000-03-02 2002-08-08 Robinson Harriet L. DNA expression vectors and methods of use
US8623379B2 (en) * 2000-03-02 2014-01-07 Emory University Compositions and methods for generating an immune response
WO2002011748A1 (en) * 2000-08-07 2002-02-14 Sloan-Kettering Institute For Cancer Research Method and composition for immunization using mixed pools of mutated nucleic acids or peptides
AU2002305914A1 (en) * 2001-01-12 2002-10-21 Chiron Corporation Nucleic acid mucosal immunization
CN100446812C (zh) * 2001-03-08 2008-12-31 美国国有健康与人类服务部 表达修饰的hiv包膜、gag和pol基因的mva
AU2002320314A1 (en) 2001-07-05 2003-01-21 Chiron, Corporation Polynucleotides encoding antigenic hiv type c polypeptides, polypeptides and uses thereof
EP1409694A4 (en) * 2001-07-05 2006-02-08 Chiron Corp POLYNUCLEOTIDES ENCODING ANTIGENIC POLYPEPTIDES OF HIV SUBTYPE B AND / OR SUBTYPE C, POLYPEPTIDES AND USES THEREOF
GB0118532D0 (en) * 2001-07-30 2001-09-19 Isis Innovation Materials and methods relating to improved vaccination strategies
CA2458995C (en) * 2001-08-31 2013-04-30 Chiron Corporation Polynucleotides encoding antigenic hiv type b polypeptides, polypeptides and uses thereof
US20030170614A1 (en) * 2001-08-31 2003-09-11 Megede Jan Zur Polynucleotides encoding antigenic HIV type B polypeptides, polypeptides and uses thereof
US20070269456A1 (en) * 2001-11-05 2007-11-22 Lasher Alfred W DNA-based plasmid formulations and vaccines and prophylactics containing the same
US20030228327A1 (en) * 2001-11-05 2003-12-11 Lasher Alfred W. DNA-based plasmid formulations and vaccines and prophylactics containing the same
GB2396814B (en) 2001-11-30 2006-07-19 Isis Innovation Fowlpox vector
US7094410B2 (en) * 2002-03-02 2006-08-22 The Scripps Research Institute DNA vaccine against proliferating endothelial cells and methods of use thereof
US6923958B2 (en) * 2002-03-02 2005-08-02 The Scripps Research Institute DNA vaccines encoding CEA and a CD40 ligand and methods of use thereof
US20040106566A1 (en) * 2002-05-17 2004-06-03 Shi-Lung Lin RNA-splicing and processing-directed gene silencing and the relative applications thereof
DE60324678D1 (de) * 2002-07-18 2008-12-24 Univ Washington N t-lymphozyten und damit identifizierte hsv-antigene
US7901690B2 (en) * 2002-12-03 2011-03-08 University Of Massachusetts Polyvalent, primary HIV-1 glycoprotein DNA vaccines and vaccination methods
BRPI0410422A (pt) 2003-05-12 2006-05-30 Univ Florida materiais e processos para para imunização contra infecção por fiv
US7658927B2 (en) * 2003-05-12 2010-02-09 University Of Florida Research Foundation, Inc. Materials and methods for immunizing against FIV infection
US8076060B2 (en) * 2003-08-04 2011-12-13 Emil William Chynn Vaccination and immunotherapy as new therapeutic modalities in the treatment of glaucoma
AU2004270275B2 (en) * 2003-09-09 2010-02-18 Virxsys Corporation Lentivirus vector-based approaches for generating an immune response to HIV humans
WO2005027840A2 (en) * 2003-09-15 2005-03-31 Chiron Corporation Combination approaches for generating immune responses
CN1913919B (zh) 2003-09-15 2011-10-19 美国政府健康及人类服务部 基于hiv多进化枝的env的hiv疫苗
US20050175627A1 (en) * 2003-09-24 2005-08-11 Oxxon Therapeutics Ltd. HIV pharmaccines
US7622125B2 (en) 2004-05-05 2009-11-24 Novartis Vaccines And Diagnostics, Inc. Polycistronic HIV vector constructs
CN100549021C (zh) * 2004-05-27 2009-10-14 森托科尔公司 猕猴前列腺特异性抗原
EP1773406A4 (en) * 2004-06-15 2008-09-03 Centocor Inc METHOD FOR SCREENING AGENTS AGAINST DISEASE OF HUMAN PROSTATE
EP2397490B1 (en) 2004-07-16 2013-09-04 THE UNITED STATES OF AMERICA, represented by THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES Vaccine constructs and combinations of vaccines designed to improve the breadth of the immune response to diverse strains and clades of HIV
WO2006044864A2 (en) * 2004-10-19 2006-04-27 Duke University Vaccine adjuvant
WO2006050394A2 (en) 2004-11-01 2006-05-11 Novartis Vaccines And Diagnostics Inc. Combination approaches for generating immune responses
EP1828390B1 (en) * 2004-12-15 2012-06-13 The University Of North Carolina At Chapel Hill Chimeric vectors
WO2008048984A2 (en) * 2006-10-18 2008-04-24 St. Jude Children's Research Hospital Methods and compositions for preparing a universal influenza vaccine
EP2396343B1 (en) 2009-02-11 2017-05-17 The University of North Carolina At Chapel Hill Modified virus vectors and methods of making and using the same
EA025417B1 (ru) * 2010-11-22 2016-12-30 Борис Славинович ФАРБЕР Вакцины с повышенной иммуногенностью и способы их получения
WO2012106363A2 (en) 2011-01-31 2012-08-09 Intellect Neurosciences Inc. Treatment of tauopathies
ES2606511T3 (es) 2011-04-06 2017-03-24 Biovaxim Limited Composiciones farmacéuticas para prevenir y/o tratar una enfermedad por VIH en seres humanos
MX2014005548A (es) 2011-11-14 2014-08-21 Novartis Ag Complejos inmunogenicos de carbomeros polianionicos y polipeptidos env y metodos de manufactura y usos de los mismos.
US9833503B2 (en) 2012-02-24 2017-12-05 President And Fellows Of Harvard College Methods for displaying polypeptides and uses thereof
PL3390430T3 (pl) * 2015-12-15 2020-03-31 Janssen Vaccines & Prevention B.V. Antygeny ludzkiego wirusa niedoboru odporności, wektory, kompozycje i sposoby ich zastosowania
CN113874078B (zh) 2019-04-05 2025-05-06 Tauc3生物制品有限公司 抗tauc3抗体及其应用
IT202100000569A1 (it) * 2021-01-14 2022-07-14 Evobiotech S R L Composizione comprendente vescicole extracellulari vegetali ingegnerizzate e suo impiego come vaccino

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5198214A (en) * 1983-08-31 1993-03-30 Stolle Research & Development Corporation Anti-mastitis polyvalent vaccine, method of administration and method for production thereof
NZ217645A (en) * 1985-09-25 1991-11-26 Oncogen Recombinant viruses expressing lav/htlv-iii related epitopes and vaccine formulations
US5169763A (en) * 1986-04-08 1992-12-08 Transgene S.A., Institut Pasteur Viral vector coding glycoprotein of HIV-1
EP0243029A1 (en) * 1986-04-08 1987-10-28 THE UNITED STATES OF AMERICA as represented by the Secretary United States Department of Commerce Recombinant vaccinia virus expressing human retrovirus gene
US5081226A (en) * 1986-12-30 1992-01-14 The United States Of America As Represented By The Department Of Health And Human Services Synthetic peptides sharing sequence homology with the HIV envelope protein
EP0469089B1 (en) * 1989-04-18 1997-11-19 Applied Biotechnology, Inc. Generation of hybrid genes and proteins by virus-mediated recombination
DE69233080T2 (de) * 1991-06-14 2004-04-15 Connaught Technology Corp., Greenville Rekombinanter hiv-spezifischer impfstoff aus poxviru
US5643578A (en) * 1992-03-23 1997-07-01 University Of Massachusetts Medical Center Immunization by inoculation of DNA transcription unit
ATE475668T1 (de) * 1994-01-27 2010-08-15 Univ Massachusetts Medical Immunisierung durch impfung von dns transkriptionseinheit
FR2728794B1 (fr) * 1994-12-30 1997-03-21 Rhone Merieux Vaccin recombinant aviaire a base de virus herpes aviaire, notamment contre la maladie de gumboro

Also Published As

Publication number Publication date
EP0876498A1 (en) 1998-11-11
BG64711B1 (bg) 2005-12-30
EP0876498B1 (en) 2004-10-06
US5846546A (en) 1998-12-08
CN1229501C (zh) 2005-11-30
US5741492A (en) 1998-04-21
AP1200A (en) 2003-08-29
KR100571479B1 (ko) 2007-06-07
PL188641B1 (pl) 2005-03-31
RO120268B1 (ro) 2005-11-30
TR199801418T2 (xx) 1998-10-21
UA73712C2 (en) 2005-09-15
JP2007259870A (ja) 2007-10-11
CN1214083A (zh) 1999-04-14
IL125497A0 (en) 1999-03-12
AP9801325A0 (en) 1998-09-30
IL125497A (en) 2007-07-04
CZ229398A3 (cs) 1998-12-16
NO983377D0 (no) 1998-07-22
NZ331024A (en) 2000-02-28
CA2243570A1 (en) 1997-07-31
HK1016218A1 (en) 1999-10-29
ATE278790T1 (de) 2004-10-15
DE69731075T2 (de) 2006-03-09
EA002390B1 (ru) 2002-04-25
KR19990081931A (ko) 1999-11-15
HU224344B1 (hu) 2005-08-29
BG102712A (en) 1999-04-30
DK0876498T3 (da) 2005-02-07
EA199800638A1 (ru) 1999-02-25
AU709174B2 (en) 1999-08-26
EP1378516A1 (en) 2004-01-07
US6086891A (en) 2000-07-11
HU0402182D0 (en) 2004-12-28
PL328193A1 (en) 1999-01-18
JP2000504326A (ja) 2000-04-11
AU1829997A (en) 1997-08-20
NO322261B1 (no) 2006-09-04
GEP20032902B (en) 2003-02-25
HUP9900389A3 (en) 2001-06-28
CZ296575B6 (cs) 2006-04-12
WO1997027311A1 (en) 1997-07-31
ES2230596T3 (es) 2005-05-01
BR9707611A (pt) 1999-07-27
CA2243570C (en) 2001-08-14
IL156919A0 (en) 2004-02-08
OA10814A (en) 2003-01-28
NO983377L (no) 1998-09-23
HUP9900389A2 (hu) 1999-06-28
DE69731075D1 (de) 2004-11-11

Similar Documents

Publication Publication Date Title
BR9707611A (pt) Mistura de vetores de vaccinia recombinantes como vacinas polienv para hiv
NO996133D0 (no) Olje-i-vann-vaksinesammensetninger
NO20002084L (no) Progestinterapi med kontrollert blødning
DE69808479D1 (de) Sicherheitsrasierer
MA24614A1 (fr) Tensioactifs alkylbenzensulfonates ameliores
NO20003303D0 (no) Vaksine
IS5449A (is) Umbreytt K-vítamín-háð fjölpeptíð
DK1028727T3 (da) Bestanddele til forögelse af hudpenetration
PT719864E (pt) Vacina viva recombinante aviaria usando como vector um herpesvirus aviario
NO2010013I2 (no) Rekombinant FSH-CTP
ATE301419T1 (de) Verbesserte mischdüse
DE69800383D1 (de) Influenza Vaccine
DE59801355D1 (de) Schere
ID18351A (id) Vaksin hidup rekombinan avian, yang sebagai vektor menggunakan virus laringotracheitis menular avian
IS5536A (is) Efnablanda fyrir snyrtivörur
ID17860A (id) Komposisi vaksin
DE69827484D1 (de) Stabilisierte tibolone zubereitungen
ITMI991657A0 (it) Procedimento per la preparazione di ossidi olefinici
DK0887822T3 (da) Sikkerhedsafbryder
DE69800963D1 (de) Sicherheitsrasierer
FI972617A7 (fi) Kanavanvaihto tukiasemassa
ATE295182T1 (de) Zusammensetzungen zur immunverstärkung von impfstoffen
DK0901815T3 (da) Zn-Cu-Al-Blandingsoxid-katalysator i tabletform
BR9710019A (pt) Mistura de virginiamicina
FR2770250B1 (fr) Targette de securite